Picking fights no one has ever won before.

We’re going there.
And this team is leading the way.

Company Overview

Overcoming science’s hardest obstacles is our highest priority.

Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry leaders.

Frustrated by the fact that so many devastating diseases still lack adequate treatments, we’ve made it our mission to discover, develop, manufacture, and deliver therapies that meaningfully improve the lives of patients with severe and rare diseases.

Our success depends on rallying the best people, partners, and science. It hinges on fearlessly creating paths forward that no one has attempted before. And of course, it means striving to develop and deliver the truly transformational.

Following the science wherever it goes.

Developing and delivering transformative therapies starts with access to high-quality product candidates. The trick is finding them. At Rallybio, we believe we have two unique advantages. First, our decades of experience in drug discovery, research, development, regulatory strategy, and manufacturing help us more effectively source, identify, and evaluate therapeutic targets and product candidates with a higher probability of success. Just as important, we have an extensive network of relationships with academic clinical centers and leaders in industry worldwide who know just what we’re looking for — and what we are capable of achieving.
“So many devastating diseases still lack adequate treatments. To us, that’s unacceptable. We refuse to settle for anything short of delivering therapies that truly transform the lives of patients.”
– Martin Mackay, Ph.D.,
Co-Founder and Executive Chairman

Working in parallel paths to make unparalleled progress.

Our experienced drug development executives have been integral to the approvals of more than 30 drugs at leading global pharmaceutical and biotech companies.

Leveraging our team’s expertise, we continue to expand our diversified portfolio of product candidates in order to significantly improve the lives of patients suffering from devastating and rare diseases.

Taking the paths of most resistance.

Our Team

Driving product candidates through clinical development to regulatory approvals isn’t easy, but we know it’s possible.

Over the course of their careers, members of our team have played critical roles in developing and implementing novel clinical trial designs and have successfully conducted clinical trials in never-before-treated patient populations. Our unique collective experience positions us to efficiently and expertly execute at each step in the research and development process, significantly enhancing the value we can bring to product candidates and to patients.

Rachael Alford, Ph.D.
Róisín Armstrong, Ph.D.
Sharon Arrol, Ph.D.
Ami Bavishi
Michael Bombara
Derek Brown, MBA
Danielle Camputaro
Zhiliang Cheng, Ph.D.
Vertrice Daniels
Laura A. Ekas, Ph.D.
Michael Greco, JD
Melissa Haskell, DVM, DABT
Amanda Hayward, Ph.D.
Lauren Kriss
Laura Lawrence
Eric Levesque, CPA
Jonathan I. Lieber
Mark Ma, M.D., M.Sc.
Martin Mackay, Ph.D.
Melissa Muise
Kiran Patki, M.D., M.Sc.
Steve Ryder, M.D.
Jackie Schumacher
Douglas Sheridan, Ph.D.
Kimberly Sparkman
Michael Sullivan, PMP
Samantha Tracy
Tara Tunucci
Steve Uden, M.D.
Carrie White, MBA

Our Newest Team Members

Board of Directors

Helen M. Boudreau
Wendy K. Chung, M.D., Ph.D.
Rob Hopfner, R.Ph., Ph.D., MBA
Ron Hunt, MBA
Lucian Iancovici, M.D.
Hui Liu, Ph.D.
Martin Mackay, Ph.D.
Christine A. Nash, MBA
Kush M. Parmar, M.D., Ph.D.
Paula Soteropoulos
Steve Uden, M.D.

Commitment to Patients

We’re not here to make an incremental difference.

As many as 30 million Americans or more — and a considerably larger number of people worldwide — are affected by rare diseases, which number more than 7,000. Our goal is to deliver new and transformative medicines to patients worldwide so they can become unbound and undefined by the diseases from which they suffer.

ANYTHING IS POSSIBLE WHEN WE RALLY

When we RallyTogether, we can uplift each other, our patients, our community, and the world around us.

At Rallybio, our goal is to meaningfully improve the lives of patients suffering from severe and rare diseases by harnessing the decades of knowledge and experience of our team to deliver transformative therapies.

Internally, we foster our inclusive culture and values to cultivate a great place to work, where our employees can be candid, courageous, and tenacious in their pursuits, as we work every day to deliver on our mission.

While Rallybio might be a small company, we believe we can make a big impact. We believe that proactively launching our ESG program (and our Impact Report) will help strengthen our foundation to ensure our company to ensure that we can deliver long-term value for our stakeholders and lasting impact for our patients.

Learn more and read our inaugural Impact Report.